



**18th March 2009**

## **NORGINE MAKES A NEW APPOINTMENT IN BUSINESS DEVELOPMENT**

Norgine, the leading European specialty pharmaceutical company, today announced that Angela Boyhan has joined the company as Director, Evaluation and Alliances. In this role she will be reporting to Paul Pay, Vice President Corporate and Business Development.

Most recently Angela was Project & Portfolio Manager, Oncology Commercial Centre of Excellence, where she was responsible for project management of oncology product launches in Europe and oncology portfolio management. Angela previously held roles as Project Manager and Leader at GSK, leading product development teams across different stages of development in Neurology, Infectious Diseases and Oncology.

Angela holds a PhD in Biochemistry from University College Galway, and a BSc from Dublin City University, Ireland.

**ENDS**

**If you would like any further information, or to set up an interview please contact:**

Medicom Group: Olivia Spiro on 020 8481 8129 ([olivias@medicomgroup.com](mailto:olivias@medicomgroup.com)) or Sarah Dyson on 020 8481 8145 ([sdyson@medicomgroup.com](mailto:sdyson@medicomgroup.com)).

### **Notes to editor**

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2007 Norgine's sales were €220 million, the 21st consecutive year of double-digit growth. The company employs over 1,000 people of whom around 400 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL<sup>®</sup> for the treatment of chronic constipation and faecal impaction, MOVIPREP<sup>®</sup> a new generation bowel cleansing preparation, KLEAN-PREP<sup>®</sup> for bowel preparation prior to colonoscopy, and ORAMORPH<sup>®</sup> for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. In addition to its site at Hengoed, Norgine also has a manufacturing site at Dreux in France.

Norgine's website is [www.norgine.com](http://www.norgine.com)